Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Radial spoke head component 1 (RSPH1) is a structural protein encoded by the *RSPH1* gene and is essential for the formation and function of the radial spoke head in the axoneme, a core component of motile cilia and flagella. It plays a key role in enabling normal ciliary movement by assembling into the axonemal radial spoke complex, especially in cells bearing motile cilia such as respiratory epithelial cells and spermatogenic cells. Mutations in *RSPH1* cause a subset of primary ciliary dyskinesia (PCD), a rare genetic disorder characterized by abnormal ciliary motility and associated respiratory, reproductive, and sometimes neurological dysfunction. Phenotypic consequences in PCD include abnormal ciliary beating patterns, impaired mucociliary clearance, and associated recurrent respiratory infections[1][2][3]. RSPH1 contains multiple MORN (Membrane Occupation and Recognition Nexus) repeats, which likely contribute to its structural and regulatory roles within the axonemal complex. No current drugs target RSPH1, and its principal clinical relevance is as a causative gene in PCD rather than as a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Radial spoke head component 1 (RSPH1).